News
MTNB
--
0.00%
--
Matinas BioPharma to Present at the ICR Conference 2021
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the ICR Conference 2021 on Thursday, January 14, 2021 at 1:00 p.m. ET.
GlobeNewswire · 01/06 12:00
Matinas BioPharma to Present at the ICR Conference 2021
BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the ICR Conference 2021 on Thursday, ...
GlobeNewswire · 01/06 12:00
CHU, CHL, FUBO and SKLZ among premarket gainers
Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's
Seekingalpha · 01/05 13:27
Matinas biopharma's MAT9001 gets conditional acceptance from FDA for LYPDISO brand name
Clinical-stage biopharmaceutical company Matinas BioPharma (MTNB) announces the FDA has conditionally accepted LYPDISO as the proposed brand name for MAT9001, its treatment for cardiovascular and metabolic conditions.The United States Patent and Trademark
Seekingalpha · 01/04 14:05
Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO(TM) as the Brand Name for MAT9001
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the U.S. Food and Dru...
GlobeNewswire · 01/04 12:00
Thinking about buying stock in BioNano Genomics, Ampio Pharmaceuticals, TRACON Pharmaceuticals, eMagin Corp, or Matinas BioPharma?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNGO, AMPE, TCON, EMAN, and MTNB.
PR Newswire - PRF · 12/31/2020 13:30
Microcaps mostly among midday movers
Gainers: Professional Diversity Network (IPDN) +118%.SGOCO Group (SGOC) +85%.Bionano Genomics (BNGO) +84%.Net Element (NETE) +51%.Conifer Holdings (CNFR) +45%.Guardion Health Sciences (GHSI) +41%.Indonesia Energy Corporation (INDO) +40%.IKONICS Corporation (IKNX) +35%.Bit Digital (BTBT)
Seekingalpha · 12/30/2020 17:34
Thinking about buying stock in Gevo, Ocugen, Riot Blockchain, Matinas BioPharma, or Blink Charging?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, OCGN, RIOT, MTNB, and BLNK.
PR Newswire - PRF · 12/30/2020 15:50
These 2 Penny Stocks Are Poised to Go Boom, Say Analysts
Wall Street has mixed feelings about penny stocks. These tickers changing hands for less than $5 per share either draw investors in with their high return potential or send them running for the hills, but why?When we say high return potential, we aren’t ex...
TipRanks · 12/29/2020 16:27
Thinking about buying stock in Affimed NV, Kura Oncology, Matinas BioPharma, Uranium Energy, or Senseonics Holdings?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS.
PR Newswire - PRF · 12/07/2020 14:31
Thinking about buying stock in Affimed NV, Kura Oncology, Matinas BioPharma, Uranium Energy, or Senseonics Holdings?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS.
PR Newswire - PRF · 12/07/2020 14:31
MFGP, KODK among premarket gainers
Eastman Kodak (KODK) +76%. as DFC says no laws were broken.Greenland Technologies Holding (GTEC) +60% on launching 'electric industrial vehicle market' divisionObalon Therapeutics (OBLN) +52%.Oncternal Therapeutics (ONCT) +27% on presentation of interim phase 1/2 data
Seekingalpha · 12/07/2020 13:20
Matinas Bio to evaluate oral formulations of Gilead’s antiviral remdesivir, shares up 15%
Matinas BioPharma (MTNB) gains 15% premarket on the news of collaboration with the National Institute of Allergy and Infectious Diseases ((NIAID)), to test oral formulations of remdesivir in preclinical models.Remdesivir is owned by Gilead
Seekingalpha · 12/07/2020 11:53
Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -   -
Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -   - · 12/07/2020 11:36
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need,
Benzinga · 12/07/2020 11:35
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gileads Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet...
GlobeNewswire · 12/07/2020 11:35
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they plan to col...
GlobeNewswire · 12/07/2020 11:35
Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
GlobeNewswire · 12/07/2020 11:30
Matinas Biopharma Holdings, Inc. (MTNB) Fell Out Of Favor With Hedge Funds
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. ...
Insider Monkey · 12/03/2020 01:37
Matinas Biopharma Holdings, Inc. (MTNB) Fell Out Of Favor With Hedge Funds
Insider Monkey · 12/03/2020 01:37
Webull provides a variety of real-time MTNB stock news. You can receive the latest news about Matinas through multiple platforms. This information may help you make smarter investment decisions.
About MTNB
Matinas BioPharma Holdings, Inc., is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.
More